Dr. Lal PathLabs reported a 10.6% YoY revenue increase for Q3 FY26, driven by volume growth and favorable test mix. The company launched Sovaaka, a personalized preventive healthcare platform, and continues to expand its specialized testing capabilities. Despite a decline in the seasonal fever portfolio, YTD revenue grew by 10.8%. Focus remains on sustainable growth and strategic expansion in Tier 2 & 3 markets, with continued investment in technology and customer experience.
Financial Performance
Dr. Lal PathLabs announced a 10.6% year-over-year (YoY) increase in revenue for Q3 FY26, reaching ₹660 crore compared to ₹597 crore in the same quarter last year. For the nine months ended December 2025, revenue stood at ₹2,060 crore, reflecting a 10.8% growth. EBITDA before exceptional items for Q3 FY26 was ₹179 crore with a margin of 27.2%. Profit after tax for Q3 FY26 stood at ₹91 crore.
Strategic Initiatives
The company launched Sovaaka, a personalized preventive healthcare platform, marking a shift towards science-led disease prevention. Dr. Lal PathLabs is also expanding its specialized testing capabilities, including oncology and genomics. Expansion into Tier 3 and Tier 4 markets continues via the franchisee-led model.
Operational Metrics
Revenue per patient for Q3 FY26 was ₹927, a 7.7% increase YoY. Tests per patient increased to ₹3.11. Patient volume growth was 2.7% in Q3 due to a decline in the seasonal fever portfolio. The company passed on GST reduction benefits to patients through price reductions. The B2C share is approximately 75% of the revenue.
Future Outlook
Dr. Lal PathLabs is focused on sustainable growth and healthy profitability, with continued investment in quality and customer experience. The company maintains a robust balance sheet with net cash and cash equivalents of ₹1,411 crore as of December 31, 2025. Board approved an interim dividend of ₹3.5 per share. The company plans to continue evaluating inorganic opportunities that align with strategic growth areas.
Source: BSE
